Pharma & Biotech

All eyes are on May 5th. When BioNTech reports its first-quarter earnings, investors will scrutinize more than just revenue from...

The coming days represent a defining moment for Bayer AG as two pivotal events converge, threatening to either cap a...

ImmunityBio finds itself navigating a stark contradiction. While its commercial engine is firing on all cylinders, a brewing legal storm...

ImmunityBio finds itself navigating a stark dichotomy. While the biotech firm reports its strongest commercial quarter to date, it is...

A critical legal hearing scheduled for May 6 in Delaware could resolve a major uncertainty hanging over gene therapy developer...

ImmunityBio is navigating a stark divide. While its commercial engine, driven by the cancer drug Anktiva, is firing on all...

The U.S. Food and Drug Administration has delivered a potentially fatal blow to Replimune Group Inc., issuing a second complete...

The stock of telehealth provider Hims & Hers has been under significant pressure, trading roughly 40 percent below its level...

ImmunityBio's stock is navigating a volatile path, caught between explosive commercial growth for its bladder cancer drug and a rising...

Positive clinical results for a late-stage cancer drug candidate have strengthened BioNTech's strategic pivot away from its pandemic-era business. The...